Antiplatelet effects of some aporphine and phenanthrene alkaloids in rabbits and man.
Two aporphines (boldine and laurolitsine) and five phenanthrene alkaloids (litebamine, secoboldine, N-cyanosecoboldine, N-methylsecoglaucine and N-methylsecopredicentrine) were evaluated in-vitro for their ability to inhibit platelet aggregation. All seven alkaloids inhibited aggregation of rabbit platelets and inhibited the release of ATP induced by arachidonic acid and collagen in rabbit platelets. Those aggregations induced by platelet-activating factor (PAF), thrombin, U46619 and ADP were inhibited by the three N-substituted secoboldine derivatives only. Thromboxane B2 formation caused by arachidonic acid was also suppressed by these compounds. They did not affect the generation of [3H]inositol monophosphate caused by collagen, PAF and thrombin in the presence of indomethacin. Platelet cyclic AMP level was unaffected by litebamine, but was increased by N-methylsecoglaucine. Litebamine suppressed the secondary aggregation, but not the primary aggregation, induced by ADP and adrenaline in platelet-rich plasma from man, whereas N-methylsecoglaucine inhibited both primary and secondary aggregation. It is concluded that the antiplatelet effect of these seven aporphine and phenanthrene alkaloids is mainly a result of inhibition of thromboxane A2 formation; N-methylsecoglaucine has additional antiplatelet activity as a result of increasing the levels of platelet cyclic AMP.
Teng
C M
CM
Pharmacological Institute, College of Medicine, National Taiwan University, Taipei, Taiwan.
Hsueh
C M
CM
Chang
Y L
YL
Ko
F N
FN
Lee
S S
SS
Liu
K C
KC
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000633:toxicity; D000244:Adenosine Diphosphate / Q000633:toxicity; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001060:Aporphines / Q000378:metabolism / Q000494:pharmacology*; D016718:Arachidonic Acid / Q000633:toxicity; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D003094:Collagen / Q000633:toxicity; D000242:Cyclic AMP / Q000378:metabolism; D006139:Guaiacol / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology; D007553:Isotope Labeling; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology*; D008297:Male; D010616:Phenanthrenes / Q000378:metabolism / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000633:toxicity; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011804:Quinolines / Q000494:pharmacology; D011817:Rabbits; D011863:Radioimmunoassay; D013329:Structure-Activity Relationship; D013917:Thrombin / Q000633:toxicity; D013929:Thromboxane B2 / Q000378:metabolism; D014662:Vasoconstrictor Agents / Q000633:toxicity
D001060:Aporphines; D007546:Isoquinolines; D016859:Lipoxygenase Inhibitors; D010616:Phenanthrenes; D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; D011804:Quinolines; D014662:Vasoconstrictor Agents; C109135:secoboldine; C109134:litebamine; C081279:aporphine; D016718:Arachidonic Acid; D013929:Thromboxane B2; C109133:laurolitsine; D000244:Adenosine Diphosphate; D006139:Guaiacol; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; C011686:boldine; D000255:Adenosine Triphosphate; D003094:Collagen; D000242:Cyclic AMP; D013917:Thrombin